The processing and rigorous analysis of the health data generated by healthcare institutions is essential for organizational decision-making, improving clinical practice, and advancing research and innovation. With this conviction, Vall d’Hebron has been working since 2022 on the deployment of a secure and interoperable health data space that will make millions of high-quality health data points available to the Campus’ scientific and healthcare community.

This is the VHTeDades project, which is part of the European Health Data Space promoted by the European Union and was presented today at Mobile World Congress (MWC) Barcelona by the Director of Information Systems at Vall d’Hebron University Hospital, Susanna Aussó.

High-quality data to support professionals and managers in decision-making

This pioneering project aims to collect and organize health data in a secure and standardized way; ensure the quality of this data so it can be shared and used to help professionals and managers make more precise, value-driven decisions; and participate in international health research networks and projects. All of this while guaranteeing data privacy and traceability and complying with current regulations.

VHTeDades is based on on-premise technology. This means that both the software and servers are installed and operated physically within Vall d’Hebron’s facilities rather than in the cloud. The institution is fully responsible for the management, maintenance, security, and updating of its own resources and licenses, ensuring the robustness of the environment.

Vall d’Hebron will manage the entire lifecycle of electronic health data generated by the Campus through its daily activity and will facilitate its use among professionals at the Hospital and its research institutes, the Vall d’Hebron Research Institute (VHIR) and the Vall d’Hebron Institute of Oncology (VHIO). It is also working to enable the sharing of this data within a federated network with other healthcare institutions across Spain to maximize its scientific and healthcare impact.

VHIR’s participation in artificial intelligence, innovation, and biomedical entrepreneurship initiatives

As part of the program “AI in Healthcare: Hype or Hope?”, organized by AstraZeneca at 4YFN, the head of the Medical Molecular Imaging research group at VHIR, Raul Herance, participated in the session From Algorithms to Impact: How Artificial Intelligence Is Transforming Care at Scale. The session, held on March 4 at the Sky Stage of 4YFN, focused on how artificial intelligence solutions are moving from pilot phases to applications with real impact on healthcare systems.

During the discussion, international experts addressed how these technologies can help improve biomedical research, optimize healthcare processes, and enable more personalized medicine. Raul Herance shared insights into the research carried out at VHIR and the Vall d’Hebron Campus in the field of medical imaging and the application of new technologies to advance disease diagnosis and monitoring.

Recognition of female entrepreneurship

The presence of women linked to VHIR has also been highlighted in the field of innovation and biomedical entrepreneurship. Within the framework of 4YFN, three spin-offs originating from VHIR (D-Sight, MIMARK, and Heecap) were recognized among the Top 10 Women Entrepreneurs in Catalonia 2026, an initiative promoted by EAE Barcelona.

Among the recognized professionals is Eva Colás, associated with MIMARK and co-head of the Biomedical Research Group in Gynecology at VHIR. This recognition highlights Vall d’Hebron’s ability not only to generate scientific knowledge but also to promote business initiatives led by women that transform research into practical solutions.

Spin-offs with solutions to improve patient care

VHIR also took part in MWC Barcelona by presenting business projects arising from its research activity. On March 5, institute researchers delivered micropresentations (pitches) to showcase two spin-offs created from the center’s research: Bsure Medical and Tensor Medical.

Bsure Medical is a VHIR-linked spin-off, created in 2020, operating in the field of biotechnology and personalized medicine. Its first product is a genetic kit for predicting severe adverse reactions to subcutaneous implants, aimed at improving patient safety and supporting clinical decision-making prior to procedures. The company has a strategic alliance with the multinational FAGRON as an industrial partner and investor.

Tensor Medical, created in 2021 with VHIR participation, develops artificial intelligence solutions applied to medical imaging to improve the care of people with multiple sclerosis. Its technology helps neuroradiologists more accurately quantify new brain lesions in magnetic resonance imaging scans, reducing errors associated with visual assessment and increasing diagnostic sensitivity. Preclinical studies with an initial functional prototype show a significant improvement in lesion detection, reinforcing the potential of this tool to optimize patient monitoring and therapeutic decision-making.